Purchase this article with an account.
S. Yeh, K. K. Wroblewski, R. Buggage, Z. Li, S. K. Kurup, H. N. Sen, S. Dahr, J. Ragheb, T. A. Waldmann, R. B. Nussenblatt; Daclizumab for Active, Non-Infectious, Sight-Threatening Uveitis: A Phase II Pilot Study. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3891. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
This study was designed to provide preliminary data regarding the safety and efficacy of high-dose humanized anti-IL-2 receptor (daclizumab) therapy for the treatment of active intermediate, posterior or panuveitis.
Five patients were recruited into this non-randomized, prospective pilot study of high-dose intravenous induction daclizumab therapy (8 mg/kg at day 0, 4 mg/kg at day 14). Patients who did not meet a safety endpoint at the 3-week follow-up were given the option of continuing therapy with subcutaneous daclizumab 2 mg/kg for 52 weeks. The primary outcome assessed was a 2-step decrease in vitreous haze at the day 21 follow-up visit. Secondary outcomes included visual acuity, cystoid macular edema, retinal vascular sheathing leakage by fluorescein angiography, anterior chamber and vitreous cellular inflammation, and vitreous haze.
4 male patients and 1 female patient were enrolled. Diagnoses included birdshot retinochoroidopathy (2 pts), Vogt-Koyanagi-Harada’s disease, bilateral idiopathic panuveitis and bilateral idiopathic intermediate uveitis. By week 4, four of five patients demonstrated a 2-step decrease in vitreous haze. One participant did not meet this criteria until week 20, but all 5 patients maintained stability in vitreous haze grade throughout their follow-up periods. At enrollment, mean visual acuity (10 eyes in five patients) was 69.2 ETDRS letters and following treatment was 78.2 letters (p=0.08). Anterior chamber cell, vitreous cell, and vitreous haze also improved in the majority of eyes. Specifically, anterior chamber cells decreased in 8 of 9 eyes (88%), vitreous cell decreased in 6 of 10 eyes (60%) and vitreous haze decreased in 8 of 8 eyes. Adverse events were generally mild except for one episode of left-lower lobe pneumonia requiring hospitalization and treatment.
Clinical Trial: :
This PDF is available to Subscribers Only